| Revision as of 19:37, 10 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Dr← Previous edit |
Latest revision as of 06:05, 11 December 2024 edit undoAlyInWikiWonderland (talk | contribs)Autopatrolled, Extended confirmed users81,798 edits Add synonyms. |
| (42 intermediate revisions by 24 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
| ⚫ |
| verifiedrevid = 447764702 |
|
|
|
| Watchedfields = changed |
| ⚫ |
| IUPAC_name = 1-(benzodioxol-5-ylmethyl)piperazine |
|
|
⚫ |
| verifiedrevid = 449584568 |
|
⚫ |
| IUPAC_name = 1-(Benzodioxol-5-ylmethyl)piperazine |
|
| image = MDBZP.svg |
|
| image = MDBZP.svg |
|
| width = 160 |
|
| width = 160 |
| Line 7: |
Line 10: |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
|
| legal_DE = NpSG |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 32231-06-4 |
|
| CAS_number = 32231-06-4 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 512G6R381X |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = 94426 |
|
| PubChem = 94426 |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
| ChemSpiderID = 85214 |
|
|
| synonyms = MDBZP; MDBP; Piperonylpiperazine; ''N''-Piperonylpiperazine |
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=12 | H=16 | N=2 | O=2 |
|
| C=12 | H=16 | N=2 | O=2 |
|
|
| smiles = c1cc2c(cc1CN3CCNCC3)OCO2 |
|
| molecular_weight = 220.268 g/mol |
|
|
|
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChI = 1S/C12H16N2O2/c1-2-11-12(16-9-15-11)7-10(1)8-14-5-3-13-4-6-14/h1-2,7,13H,3-6,8-9H2 |
|
|
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChIKey = NBOOZXVYXHATOW-UHFFFAOYSA-N |
|
}} |
|
}} |
|
|
|
|
|
'''1-(3,4-Methylenedioxybenzyl)piperazine''' ('''MDBZP'''; '''Piperonylpiperazine''') is a ] of the ] ] related to ] (BZP). In the book ] it is speculated that MDBZP might have effects similar to the drug ] (MDMA; "]") because of the presence of the 3,4-methylenedioxy group on the benzene ring; however, once the compound was tested in humans this theory was shown to be incorrect. |
|
'''1-(3,4-Methylenedioxybenzyl)piperazine''' ('''MDBZP''', '''piperonylpiperazine''') is a ] of the ] ] related to ] (BZP). MDBZP has been sold as a ]<ref>{{cite journal | vauthors = Maurer HH, Kraemer T, Springer D, Staack RF | title = Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis | journal = Therapeutic Drug Monitoring | volume = 26 | issue = 2 | pages = 127–31 | date = April 2004 | pmid = 15228152 | doi = 10.1097/00007691-200404000-00007 | s2cid = 9255084 }}</ref> and has even been found as an ingredient in street ] pills.{{cn|date=January 2016}} |
|
|
|
|
MDBZP has been sold as a "]" with supposed recreational properties, and has even been found as an ingredient in street "]" pills. However, MDBZP is only a very mild stimulant, and does not produce ], empathogenic or ] effects. The prominent side effects produced by MDBZP are ], ] and ], but at high doses it has been known to cause ]. MDBZP thus has all of the negative side effects of other piperazine derivatives, but without any of the positive effects that might make these drugs desirable to consumers.{{Citation needed|date=August 2010}} |
|
|
|
|
|
|
== See also == |
|
== See also == |
|
|
* ] (MDMA) |
|
* ] (BZP) |
|
|
|
* ] |
|
* ] (MBZP) |
|
|
* ] (DBZP) |
|
|
* ] (mCPP) |
|
|
* ] (TFMPP) |
|
|
* ] (2C-B-BZP) |
|
|
* ] (pFPP) |
|
|
* ] (MeOPP) |
|
|
* ] |
|
|
|
|
|
|
== References == |
|
== References == |
|
⚫ |
{{Reflist}} |
|
{{Unreferenced|date=December 2007}} |
|
|
|
|
| ⚫ |
{{Reflist|2}} |
|
|
|
==External links== |
|
|
* {{cite web | url =https://www.who.int/medicines/areas/quality_safety/5.3eMDBZPpre-review.pdf | title =1-(3-4-methylendioxybenzyl)piperazine (MDBZP) Pre-Review Report | author = Expert Committee on Drug Dependence | date = 8 June 2012 | publisher = World Health Organization}} |
|
|
|
|
|
{{Stimulants}} |
|
{{Stimulants}} |
|
|
{{Monoamine releasing agents}} |
|
{{Adrenergics}} |
|
|
{{Dopaminergics}} |
|
|
{{Serotonergics}} |
|
|
{{Piperazines}} |
|
{{Piperazines}} |
|
|
|
|
| ⚫ |
] |
|
|
] |
|
] |
|
⚫ |
] |
|
|
] |
|
|
|
|
|
|
|
|